Screener
Krystal Biotech, Inc. KRYS Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 120,238 | 114,234 |
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 1,198,257 | 1,194,261 |
| Accumulated other comprehensive (loss) gain | (1,623) | 1,136 |
| Retained earnings | 80,095 | 24,163 |
| Total stockholders’ equity | 1,276,729 | 1,219,560 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s common stock?
- Krystal Biotech, Inc. (KRYS) reported common stock of 80M in Q1 2026.
- How has Krystal Biotech, Inc.'s common stock changed year-over-year?
- Krystal Biotech, Inc.'s common stock decreased by 0.0% year-over-year, from 80M to 80M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Krystal Biotech, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude